名臣健康(002919) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥216,717,972.68, representing a 135.55% increase compared to ¥92,005,273.17 in the same period last year[7] - Net profit attributable to shareholders reached ¥62,676,044.09, a significant increase of 937.66% from ¥6,040,118.93 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥61,816,134.13, up 1,648.06% from ¥3,536,279.25 in the previous year[7] - Basic earnings per share rose to ¥0.51, reflecting a 920.00% increase compared to ¥0.05 in the same period last year[7] - The weighted average return on equity improved to 9.13%, up 8.07 percentage points from 1.06% year-on-year[7] - The company's operating revenue for Q1 2021 reached CNY 216,717,972.68, a 135.55% increase compared to CNY 92,005,273.17 in Q1 2020, primarily due to the consolidation of two new subsidiaries and growth in the daily chemical sector[15] - The company reported a significant increase in R&D expenses, which rose by 551.76% to CNY 22,359,923.96 in Q1 2021, driven by the consolidation of two new subsidiaries[15] - The company reported a basic and diluted earnings per share of ¥0.51, up from ¥0.05 in the previous year[43] - The company achieved an operating profit of ¥63,385,335.93, a significant increase from ¥7,068,981.61 in the previous period[42] - The total profit for the current period was ¥63,421,855.30, compared to ¥7,064,988.42 in the previous period[42] Cash Flow and Investments - The net cash flow from operating activities was -¥33,167,525.98, an improvement of 31.75% compared to -¥48,653,019.41 in the same period last year[7] - Operating cash inflow for the current period was CNY 196,712,464.26, compared to CNY 90,673,649.44 in the previous period, representing an increase of approximately 117%[50] - Cash outflow from operating activities totaled CNY 229,879,990.24, up from CNY 139,326,668.85, indicating a rise of about 65%[50] - Cash inflow from investment activities was CNY 100,117,309.79, significantly higher than CNY 1,148,683.31 in the previous period[50] - Cash outflow from investment activities was CNY 117,421,980.20, down from CNY 160,800,715.58, showing a decrease of approximately 27%[50] - Net cash flow from investment activities was negative CNY 17,304,670.41, an improvement from negative CNY 159,652,032.27 in the prior period[50] - Cash and cash equivalents at the end of the period stood at CNY 147,257,380.50, compared to CNY 113,187,160.14 at the end of the previous period, reflecting an increase of about 30%[51] - The company reported a cash inflow of CNY 60,000,000.00 from investment recovery during the current period[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥917,974,155.75, a 4.41% increase from ¥879,177,170.27 at the end of the previous year[7] - Net assets attributable to shareholders increased by 9.43% to ¥717,279,575.95 from ¥655,461,348.12 at the end of the previous year[7] - Total liabilities decreased to CNY 200,694,579.80 from CNY 223,715,822.15, a reduction of approximately 10.3%[34] - The company reported a significant reduction in short-term liabilities, totaling CNY 187,388,115.00, down from CNY 220,916,338.72, a decrease of approximately 15.2%[34] - The company's total equity increased to CNY 717,279,575.95 from CNY 655,461,348.12, reflecting a growth of approximately 9.4%[35] - The company’s retained earnings increased to CNY 252,650,781.89 from CNY 190,832,554.06, a rise of approximately 32.4%[35] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,806[11] - The company has cumulatively used CNY 11,219,700.00 of the raised funds as of March 31, 2021, with CNY 10,227,120.00 remaining in a dedicated account for future project investments[22] Regulatory and Management Practices - The company has implemented strict management protocols for raised funds, ensuring they are stored in dedicated accounts and used according to regulatory agreements[22] - The company has not engaged in any securities or derivative investments during the reporting period[18][19] - The first quarter report was not audited, which may affect the reliability of the financial data presented[62]